{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-029558","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.596929+00:00","generated_at":"2026-06-18T09:13:52.966024+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rigel reports Q4 2022 net income $1.4M on record TAVALISSE sales of $21.9M; full year revenue $120.2M","bullets":["Q4 total revenue $51.3M ($21.9M TAVALISSE + $0.9M REZLIDHIA); net income $1.4M ($0.01/share) vs net loss $22.6M in Q4'21.","Full year 2022 net loss $58.6M ($0.34/share) on revenue $120.2M, compared to net loss $17.9M in 2021.","TAVALISSE 2022 net product sales $75.8M, up 20% YoY; Q4 bottles shipped to patients/clinics a record.","REZLIDHIA launched in Dec '22, $0.9M in Q4 sales; added to NCCN Guidelines for AML in Jan '23.","Cash and investments $58.2M at Dec 31, 2022, down from $125.0M at Dec 31, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-029558","json":"https://secwatch.observer/filing/0001104659-23-029558.json","markdown":"https://secwatch.observer/filing/0001104659-23-029558.md","text":"https://secwatch.observer/filing/0001104659-23-029558.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923029558/0001104659-23-029558-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923029558/tm238702d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T09:13:52.966024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cba56f75573a6c2f216ba200e2080eb343c35364","claim":"RIGEL PHARMACEUTICALS INC reported fourth quarter and year ended December 31, 2022 results: revenue $51.3 million, net income $1.4 million, or $0.01 per basic and diluted share, EPS $0.01 per basic and diluted share.","evidence_excerpt":"EXHIBIT 99.1 Exhibit 99.1 Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update ● Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE ® net product sales of $21.9 million and REZLIDHIA TM net product sales of $0.9 million ● REZLIDHIA U.S. commercial launch continues to progress and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465923029558/0001104659-23-029558-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$51.3 million"},{"label":"Net income","value":"$1.4 million, or $0.01 per basic and diluted share"},{"label":"EPS","value":"$0.01 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}